14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
GUT vs GRX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
GRX Captures Overall Composite Edge (44.3 HOLD vs 43.7 HOLD), While GUT Leads 1–0 on Growth & Valuation Pillars
GRX Overall Winner
6-Pillar Tally: GUT 1 – 0 GRX (5 Tie)
Matrix Metrics: GUT 1 – 3 GRX
As of Nov 16, 2026, The Gabelli Healthcare & Wellness Trust (GRX) captures the overall head-to-head institutional edge over Gabelli Utility Trust (GUT) on higher Unified Composite conviction (44.3/100 HOLD vs. 43.7/100 HOLD) after splitting the core matrix 3–1 (led by composite factor balance), while GUT wins 1–0 across the 6-pillar growth and valuation breakdown. GUT trades at $5.20 (N/M Forward P/E, N/A operating margin) versus GRX at $10.58 (N/M Forward P/E, N/A operating margin).
Growth vs. Quality Trade-Off: GRX earns the overall head-to-head edge with a stronger Unified Composite Score (44.3/100 HOLD vs. GUT 43.7/100 HOLD) and 0.14β · 14% Vol risk profile, whereas GUT leads top-line expansion (N/A YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: GUT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.1); meanwhile GRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GUT vs GRX. Trailing 12-month operating profitability (GUT N/A vs GRX N/A) and valuation multiples (GUT N/M vs GRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with $142.9M market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ GUT vs GRX Key Questions & Quantitative Answers
As of Nov 16, 2026, The Gabelli Healthcare & Wellness Trust (GRX) captures the overall head-to-head institutional edge over Gabelli Utility Trust (GUT) on higher Unified Composite conviction (44.3/100 HOLD vs. 43.7/100 HOLD) after splitting the core matrix 3–1 (led by composite factor balance), while GUT wins 1–0 across the 6-pillar growth and valuation breakdown. GUT trades at $5.20 (N/M Forward P/E, N/A operating margin) versus GRX at $10.58 (N/M Forward P/E, N/A operating margin). Growth vs. Quality Trade-Off: GRX earns the overall head-to-head edge with a stronger Unified Composite Score (44.3/100 HOLD vs. GUT 43.7/100 HOLD) and 0.14β · 14% Vol risk profile, whereas GUT leads top-line expansion (N/A YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: GUT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.1); meanwhile GRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
GUT leads the Growth & Scale pillar: GUT posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with GRX at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, GUT generates N/A in USD-normalized revenue versus N/A for GRX. In operating R&D and SG&A reinvestment, GUT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GRX.
GUT and GRX trade at balanced relative valuation multiples. GUT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas GRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GUT (N/A ROE) versus GRX (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, GUT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 27% Vol realized risk). By comparison, GRX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 14% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.